UK firm links with up global drug firms to make synthetic antibodies capable of binding to targets such as tumour cells
Inside a science park lab next to the University of York, two clusters of robots are busy moving clear plates with mechanical arms as they screen many millions of molecules. The machines need only 24 hours to complete work that would usually take teams of human scientists several days.
The lab is run by Aptamer Group, a small biotech firm that has quietly carved out a leading position in the development of a highly sought after technology. Its scientists create aptamers – fragments of DNA, also known as synthetic antibodies, that are used to diagnose illnesses, or to deliver drugs to their target to fight a range of diseases including cancer.
